Adaptive Biotechnologies (ADPT) Non-Current Assets (2018 - 2026)

Adaptive Biotechnologies has disclosed Non-Current Assets across 9 years of filings, most recently posting $220.1 million for Q2 2026.

• In Q2 2026, Non-Current Assets fell 6.25% year-over-year to $220.1 million; the TTM figure through Jun 2026 stood at $856.0 million (down 13.97% YoY), while the FY2025 annual figure was $212.6 million, down 16.85% from the prior year.
• Non-Current Assets came in at $220.1 million for Q2 2026 at Adaptive Biotechnologies, up from $214.1 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $439.1 million in Q1 2022 to a low of $209.2 million in Q3 2025.
• Average Non-Current Assets over 5 years is $270.2 million, with a median of $252.7 million recorded in 2023.
• The largest YoY upside for Non-Current Assets was 42.96% in 2022 against a maximum downside of 43.44% in 2022.
• Over 5 years, Non-Current Assets stood at $294.5 million in 2022, then slipped by 14.78% to $250.9 million in 2023, then rose by 1.86% to $255.6 million in 2024, then slipped by 16.85% to $212.6 million in 2025, then gained by 3.56% to $220.1 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $220.1 million in Q2 2026, $214.1 million in Q1 2026, and $212.6 million in Q4 2025.